There are currently 843 clinical trials in Jacksonville, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including Mayo Clinic in Florida, Mayo Clinic - Jacksonville, Mayo Clinic and Mayo Clinic Florida. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Study of INBRX-109 in Conventional Chondrosarcoma
Recruiting
Randomized, blinded, placebo-controlled, Phase 2 study of INBRX-109 in unresectable or metastatic conventional chondrosarcoma patients.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
01/09/2025
Locations: Mayo Clinic - Jacksonville, Jacksonville, Florida
Conditions: Conventional Chondrosarcoma
BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With Severe Sickle Cell Disease
Recruiting
This is an open-label, single-arm, multicenter, Phase 1/2 study evaluating the safety and efficacy of the administration of autologous base edited CD34+ HSPCs (BEAM-101) in patients with severe SCD
Gender:
ALL
Ages:
Between 18 years and 35 years
Trial Updated:
01/09/2025
Locations: Mayo Clinic Florida, Jacksonville, Florida
Conditions: Sickle Cell Disease
Telerehabilitation Early After CNS Injury
Recruiting
The goal of this clinical trial is to assess the safety and feasibility of providing extra doses of rehabilitation therapy for persons with a recent stroke, traumatic brain injury (TBI) and/or spinal cord injury (SCI). The therapy treatment targets to improve arm function by introducing telerehabilitation to the bedside of participants during the inpatient rehab admission period. Participants will use a newly developed functional training system (HandyMotion) to access therapy treatment program... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/09/2025
Locations: Brooks Rehabilitation, Jacksonville, Florida
Conditions: Cerebral Stroke, Traumatic Brain Injury, Spinal Cord Injuries
EMAGINE 2.0 - Electromagnetic Field Ischemic Stroke - Novel Subacute Treatment
Recruiting
This is a multicenter study that will be conducted at approximately 20 centers and up to 30 centers, if the sample size will be increased following interim assessment. The Q Therapeutic System (BQ 3.0) is a wearable medical device that produces and delivers non-invasive, extremely-low-intensity and low-frequency, frequency-tuned electromagnetic fields in order to stimulate neuronal networks with the aim of reducing disability and promoting neurorecovery. The Q Therapeutic System (BQ 3.0) is in... Read More
Gender:
ALL
Ages:
Between 22 years and 80 years
Trial Updated:
01/08/2025
Locations: Brooks Rehabilitation Hospital, Jacksonville, Florida
Conditions: Ischemic Stroke
Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma or Recurrent Astrocytoma in Patients Undergoing Craniotomy
Recruiting
This phase I trial tests the safety, side effects, and best dose of allogenic adipose-derived mesenchymal stem cells (AMSCs) in treating patients with glioblastoma or astrocytoma that has come back (recurrent) who are undergoing brain surgery (craniotomy). Glioblastoma is the most common and most aggressive form of primary and malignant tumor of the brain. Currently, the standard of care for this disease includes surgical resection, followed by radiation with chemotherapy and tumor treating fiel... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/30/2024
Locations: Mayo Clinic in Florida, Jacksonville, Florida
Conditions: Recurrent Glioblastoma, IDH-Wildtype, Recurrent Astrocytoma, IDH-Mutant, Grade 4, Astrocytoma, Grade IV
Target ALS Biomarker Study; Longitudinal Biofluids, Clinical Measures, and At Home Measures
Recruiting
The goal of the study is to generate a biorepository of longitudinal biofluids-blood (plasma and serum), cerebral spinal fluid (CSF) and urine linked to genetics and longitudinal clinical information that are made available to the research community. To accomplish these goals, we will enroll 800 Amyotrophic Lateral Sclerosis (ALS) patients and 200 healthy controls from sites globally, over a 5 year time frame. Additionally, speech and motor function and spirometry measures will be collected bi-w... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/26/2024
Locations: Mayo Clinic, Jacksonville, Florida
Conditions: Amyotrophic Lateral Sclerosis, Movement Disorders, Degenerative Disorder, Motor Neuron Disease
Understanding of Genetics by Men At Risk for Prostate Cancer
Recruiting
With this greater certainty regarding prognosis, men with localized prostate cancer are now equipped with make better treatment planning decisions. This study is designed to investigate the understanding of prognostic genetic technology in African American and rural White men at risk for localized prostate cancer.
Gender:
MALE
Ages:
Between 40 years and 95 years
Trial Updated:
12/24/2024
Locations: Mayo Clinic in Florida, Jacksonville, Florida
Conditions: Prostate Cancer
CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations
Recruiting
This phase II trial tests how well abiraterone acetate/niraparib (CJNJ-67652000 \[niraparib/abiraterone acetate fixed-dose combination\]) and prednisone works in treating patients with castration-resistant prostate cancer that has spread from where it first started (primary site) to other places in the body (metastatic) and who have a mutation in the SPOP gene. CJNJ-67652000 (niraparib/abiraterone acetate fixed-dose combination) is a drug which stops certain cancer cells from being able to repai... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
12/23/2024
Locations: Mayo Clinic in Florida, Jacksonville, Florida
Conditions: Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Cardiac Rehabilitation Mobile-Health Fall Risk Prevention Intervention
Recruiting
The purpose of this research is to see if taking part in a structured exercise plan that is designed to improve balance and muscle strength and one that can done at home helps to improve the ability to perform standard physical tasks, confidence in balance, and health-related quality-of-life
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/20/2024
Locations: Mayo Clinic Florida, Jacksonville, Florida
Conditions: Cardiac Rehabilitation
Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age
Recruiting
This is a Phase 2a/b single arm open label study to evaluate the safety, reactogenicity, and efficacy of intracystic injection of TARA-002 in participants 6 months to less than 18 years of age for the treatment of macrocystic and mixed cystic lymphatic malformations. The Phase 2a safety lead-in, age de-escalation study is designed to establish the safety of TARA-002 in older participants 6 years to less than 18 years before proceeding to younger participants 2 years to less than 6 years, then 6... Read More
Gender:
ALL
Ages:
Between 6 months and 18 years
Trial Updated:
12/20/2024
Locations: Nemours Children's Clinic - Jacksonville, Jacksonville, Florida
Conditions: Lymphatic Malformation
CGM and Lifestyle Changes in Patients with Impaired Glucose Tolerance
Recruiting
The incidence of type 2 diabetes (T2D) in children is increasing, paralleling the rising incidence of obesity. Preventing children and adolescents from developing T2D is critical. The health benefits of lifestyle modifications are well documented in this population, but success rates are low. Obesity in children and adolescents increases the risk of not only T2D but other complications as well, such as hypertension, dyslipidemias and more. The investigators hypothesize that having real-time gluc... Read More
Gender:
ALL
Ages:
Between 10 years and 16 years
Trial Updated:
12/19/2024
Locations: Nemours Children's Clinic, Jacksonville, Florida
Conditions: Impaired Glucose Tolerance
Safety and Durability of Sirolimus for Treatment of LAM
Recruiting
The MIDAS study aims to follow male and female LAM patients who are currently taking, have previously failed or been intolerant of, or may (at some time in the future) take mTOR inhibitors (sirolimus or everolimus) as part of their clinical care. Adult female TSC patients may also enroll, with or without lung cysts.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/18/2024
Locations: Mayo Clinic Jacksonville, Jacksonville, Florida
Conditions: Lymphangioleiomyomatosis